In addition to monetary damages and the guilty pleas, the government is seeking to transform the maker of OxyContin into a public benefit company that would fund efforts to curb opioid abuse and give away drugs to prevent overdose deaths.
Nearly all of the states, plus five territories and the District of Columbia, are seeking an aggregate of $2.156 trillion from the maker of the opioid painkiller OxyContin, according to documents filed in the U.S. Bankruptcy Court Monday.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company filed for Chapter 11 Monday, but the move was criticized by some, particularly attorneys general in Massachusetts and Connecticut, amid reports that the Sackler family wired about $1 billion to overseas accounts.
Citing unnamed sources, news outlets reported that Purdue would be dissolved to create a new company that would sell OxyContin and use proceeds to pay plaintiffs in more than 2,000 lawsuits filed by governments nationwide.
American pharma companies — architects of the opioid crisis in the United States and avid hunters of new markets — stand at the ready to feed and fuel demand for painkillers in India where attitudes toward pain toleration have changed.
Citing anonymous sources familiar with the matter, news outlets reported that the family would pay $3 billion toward a proposed $10-12 billion settlement to resolve the more than 2,000 lawsuits.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The outgoing commissioner requested $55 million to aid the agency's fight against the opioid epidemic.
Reuters reported Monday that the maker of OxyContin was considering the filing so that it could negotiate claims with plaintiffs in about 2,000 lawsuits regarding the drug.
BlueCross BlueShield of Tennessee, the largest insurer in the state has announced it will no longer cover prescriptions for what was once a blockbuster pain reliever made by Purdue Pharma.
Purdue Pharma has announced a strategic partnership with Exicure, which could be worth up to $790 million and royalties if the latter's drug candidates succeed. The first disease target, psoriasis, is well outside of Purdue's painkiller market -- probably not by accident.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Macklemore, a Grammy-award winning rap artist, releases an anthem on opioid addiction and takes aim at Big Pharma and doctors.
Investigative journalism lives in some unlikely places, such as on HBO's "Last Week Tonight with John Oliver." This week, host John Oliver — you know, a comedian by trade — took a deep look at the opioid epidemic in America.
Plus, troubles at Juno Therapeutics parallel those of a failed company that many employees came from, while hospitals are starting to install cameras in the OR to monitor patient safety.
The sentencing of three of the four ex-directors of medical device manufacturer Synthes to terms ranging from five to nine months over the unauthorized use of bone cement in spinal surgery clinical trials in the case United States. v. Norian crisscrosses between regulatory issues and corporate responsibility. Synthes subsidiary Norian conducted a clinical trial using […]